Market Overview

UPDATE: Cantor Fitzgerald Lowers PT on Ironwood Pharmaceuticals on Lower than Expected Constella Pricing

Share:
Related IRWD
Empire Analyst: Sell Sucampo Pharma, It Has 50% Downside
Benzinga's Top Initiations

In a report published Tuesday, Cantor Fitzgerald analyst Irina Rivkind lowered the price target on Ironwood Pharmaceuticals (NASDAQ: IRWD) from $9 to $7 and reiterated a Sell rating on the company.

In the report, Cantor Fitzgerald commented, "On June 12 the company announced its restructured agreement with European partner Almirall. Because of lower-than expected pricing of Constella (linaclotide) in the European territories Ironwood agreed to accept lower commercial launch milestones (now $17M, down from $20M) and lower initial sales royalties (low-20% range, down from mid-20% range) in exchange for a higher sales royalty on the back end (mid-40% range) and an additional $26M in commercial milestones. We think that these "upside" milestone and royalty scenarios may never materialize. We have taken down our OUS royalty estimates in 2020 from $127M to $54M to account for lower EU pricing and royalty levels."

Ironwood Pharmaceuticals closed Monday at $11.01.

Latest Ratings for IRWD

DateFirmActionFromTo
Jan 2016Mizuho SecuritiesInitiates Coverage onBuy
Dec 2015BTIG ResearchInitiates Coverage onBuy
May 2015Leerink SwannMaintainsMarket Perform

View More Analyst Ratings for IRWD
View the Latest Analyst Ratings

Posted-In: Cantor Fitzgerald Irina RivkindAnalyst Color Price Target Analyst Ratings

 

Related Articles (IRWD)

View Comments and Join the Discussion!

Get Benzinga's Newsletters